论文部分内容阅读
通过检测 E6变体在 HPV16阳性的宫颈非典型增生 (CIN)和宫颈浸润癌 (ICC)患者中的分布 ,研究其致癌能力。方法 :用 PCR和双脱氧终止荧光法检测了 42例 E6基因点突变及其编码氨基酸改变 ,统计分布差异。结果 :2例 (5 % )为原型 ,40例 (95 % )的 E6 DNA序列中含有 1至 3个点突变 ,导致 13类 E6氨基酸残基改变 ,组合成 17种 (94% ) HPV16变体。出现频率较高的 4种变体在 CIN和 ICC病例中共同存在 ,分布无显著性差异(P>0 .0 5 )。DNA的点突变数在 CIN和 ICC病例中的分布也无显著性差异 (P>0 .0 5 )。结论 :HPV16 E6的变体多于原型 ,但是变体和原型的致癌能力没有明显差别。
The carcinogenicity of E6 variants was examined by detecting the distribution of E6 variants in patients with HPV16-positive cervical atypical hyperplasia (CIN) and cervical invasive carcinoma (ICC). Methods: 42 cases of E6 gene mutation and their encoded amino acid changes were detected by PCR and dideoxy-terminated fluorescence. Statistical differences were also observed. RESULTS: Two (5%) were prototypes and one to three point mutations were found in 40 (95%) of the E6 DNA sequences resulting in the alteration of 13 E6 amino acid residues into 17 (94%) HPV16 variants . There were no significant differences among the four variants with higher frequency of occurrence in CIN and ICC cases (P> 0.05). There was no significant difference in the distribution of point mutations in DNA between CIN and ICC cases (P> 0.05). CONCLUSIONS: There are more variants of HPV16 E6 than the prototype, but there is no significant difference between the variants and the prototype.